1. Home
  2. IIF vs MGNX Comparison

IIF vs MGNX Comparison

Compare IIF & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IIF
  • MGNX
  • Stock Information
  • Founded
  • IIF 1993
  • MGNX 2000
  • Country
  • IIF United States
  • MGNX United States
  • Employees
  • IIF N/A
  • MGNX N/A
  • Industry
  • IIF Trusts Except Educational Religious and Charitable
  • MGNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • IIF Finance
  • MGNX Health Care
  • Exchange
  • IIF Nasdaq
  • MGNX Nasdaq
  • Market Cap
  • IIF 248.2M
  • MGNX 257.3M
  • IPO Year
  • IIF N/A
  • MGNX 2013
  • Fundamental
  • Price
  • IIF $24.51
  • MGNX $3.00
  • Analyst Decision
  • IIF
  • MGNX Hold
  • Analyst Count
  • IIF 0
  • MGNX 10
  • Target Price
  • IIF N/A
  • MGNX $7.17
  • AVG Volume (30 Days)
  • IIF 45.4K
  • MGNX 496.5K
  • Earning Date
  • IIF 01-01-0001
  • MGNX 03-06-2025
  • Dividend Yield
  • IIF 13.94%
  • MGNX N/A
  • EPS Growth
  • IIF N/A
  • MGNX N/A
  • EPS
  • IIF N/A
  • MGNX N/A
  • Revenue
  • IIF N/A
  • MGNX $141,329,000.00
  • Revenue This Year
  • IIF N/A
  • MGNX $174.73
  • Revenue Next Year
  • IIF N/A
  • MGNX N/A
  • P/E Ratio
  • IIF N/A
  • MGNX N/A
  • Revenue Growth
  • IIF N/A
  • MGNX 16.68
  • 52 Week Low
  • IIF $18.95
  • MGNX $2.91
  • 52 Week High
  • IIF $24.41
  • MGNX $21.88
  • Technical
  • Relative Strength Index (RSI)
  • IIF 28.48
  • MGNX 37.54
  • Support Level
  • IIF $24.44
  • MGNX $3.00
  • Resistance Level
  • IIF $24.87
  • MGNX $3.22
  • Average True Range (ATR)
  • IIF 0.31
  • MGNX 0.17
  • MACD
  • IIF 0.01
  • MGNX -0.02
  • Stochastic Oscillator
  • IIF 13.25
  • MGNX 13.04

About IIF Morgan Stanley India Investment Fund Inc.

Morgan Stanley India Investment Fund, Inc. is the United States based non-diversified, closed-end management investment company. Its investment objective is to achieve long-term capital appreciation through investments in equity securities of Indian Issuers. The company's portfolio of investments consists of the investment in different sectors such as auto components, banks, capital markets, construction and engineering, pharmaceuticals and others.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Share on Social Networks: